403 related articles for article (PubMed ID: 30704898)
1. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.
Balwani M
Mol Genet Metab; 2019 Nov; 128(3):298-303. PubMed ID: 30704898
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.
Balwani M; Naik H; Anderson KE; Bissell DM; Bloomer J; Bonkovsky HL; Phillips JD; Overbey JR; Wang B; Singal AK; Liu LU; Desnick RJ
JAMA Dermatol; 2017 Aug; 153(8):789-796. PubMed ID: 28614581
[TBL] [Abstract][Full Text] [Related]
3. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.
Balwani M; Doheny D; Bishop DF; Nazarenko I; Yasuda M; Dailey HA; Anderson KE; Bissell DM; Bloomer J; Bonkovsky HL; Phillips JD; Liu L; Desnick RJ;
Mol Med; 2013 Apr; 19(1):26-35. PubMed ID: 23364466
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietic protoporphyria.
Lecha M; Puy H; Deybach JC
Orphanet J Rare Dis; 2009 Sep; 4():19. PubMed ID: 19744342
[TBL] [Abstract][Full Text] [Related]
5. Liver disease and erythropoietic protoporphyria: a concise review.
Casanova-González MJ; Trapero-Marugán M; Jones EA; Moreno-Otero R
World J Gastroenterol; 2010 Sep; 16(36):4526-31. PubMed ID: 20857522
[TBL] [Abstract][Full Text] [Related]
6. How I treat erythropoietic protoporphyria and X-linked protoporphyria.
Leaf RK; Dickey AK
Blood; 2023 Jun; 141(24):2921-2931. PubMed ID: 36898083
[TBL] [Abstract][Full Text] [Related]
7. [Inheritance in erythropoietic protoporphyria].
Schmitt C; Ducamp S; Gouya L; Deybach JC; Puy H
Pathol Biol (Paris); 2010 Oct; 58(5):372-80. PubMed ID: 20850938
[TBL] [Abstract][Full Text] [Related]
8. Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations.
Weiss Y; Balwani M; Chen B; Yasuda M; Nazarenko I; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):358-362. PubMed ID: 30454868
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy.
Ventura P; Brancaleoni V; Di Pierro E; Graziadei G; Macrì A; Carmine Guida C; Nicolli A; Rossi MT; Granata F; Fiorentino V; Fustinoni S; Sala R; Pinton PC; Trevisan A; Marchini S; Cuoghi C; Marcacci M; Corradini E; Sorge F; Aurizi C; Savino MG; Cappellini MD; Pietrangelo A
Eur J Dermatol; 2020 Oct; 30(5):532-540. PubMed ID: 33021473
[TBL] [Abstract][Full Text] [Related]
10. Delta-aminolevulinic acid synthase 2 expression in combination with iron as modifiers of disease severity in erythropoietic protoporphyria.
Barman-Aksözen J; Halloy F; Iyer PS; Schümperli D; Minder AE; Hall J; Minder EI; Schneider-Yin X
Mol Genet Metab; 2019 Nov; 128(3):304-308. PubMed ID: 31076252
[TBL] [Abstract][Full Text] [Related]
11. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.
Wensink D; Wagenmakers MAEM; Langendonk JG
Expert Rev Clin Pharmacol; 2021 Feb; 14(2):151-160. PubMed ID: 33507118
[No Abstract] [Full Text] [Related]
12. Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria.
Di Pierro E; Granata F; De Canio M; Rossi M; Ricci A; Marcacci M; De Luca G; Sarno L; Barbieri L; Ventura P; Graziadei G
Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054318
[TBL] [Abstract][Full Text] [Related]
13. Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study.
Minder AE; Barman-Aksoezen J; Schmid M; Minder EI; Zulewski H; Minder CE; Schneider-Yin X
Ther Adv Rare Dis; 2021; 2():26330040211065453. PubMed ID: 37181106
[TBL] [Abstract][Full Text] [Related]
14. Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.
Yasuda M; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):332-341. PubMed ID: 30737139
[TBL] [Abstract][Full Text] [Related]
15. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability.
Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X
Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834
[TBL] [Abstract][Full Text] [Related]
16. The molecular genetics of erythropoietic protoporphyria.
Elder GH; Gouya L; Whatley SD; Puy H; Badminton MN; Deybach JC
Cell Mol Biol (Noisy-le-grand); 2009 Jul; 55(2):118-26. PubMed ID: 19656460
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria.
Dickey AK; Naik H; Keel SB; Levy C; Beaven SW; Elmariah SB; Erwin AL; Goddu RJ; Hedstrom K; Leaf RK; Kazamel M; Mazepa M; Philpotts LL; Quigley J; Raef H; Rudnick SR; Saberi B; Thapar M; Ungar J; Wang B; Balwani M;
J Am Acad Dermatol; 2023 Dec; 89(6):1227-1237. PubMed ID: 36041558
[TBL] [Abstract][Full Text] [Related]
18. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.
Yasuda M; Chen B; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):320-331. PubMed ID: 30594473
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
